Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects

Journal of Infectious Diseases

Volumn 197, Issue 12, 2008, Pages 1634-1642

  Wloch, Mary K ^a   Smith, Larry R ^a   Boutsaboualoy, Souphaphone ^a   Reyes, Luane ^a   Han, Christina ^a   Kehler, Jackie ^a   Smith, Heather D ^a,f   Selk, Linda ^a   Nakamura, Ryotaro ^b   Brown, Janice M ^c   Marbury, Thomas ^d   Wald, Anna ^e   Rolland, Alain ^a   Kaslow, David ^a,g   Evans, Thomas ^a,h   Boeckh, Michael ^e  

^a VICAL INC   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ORLANDO CLINICAL RESEARCH CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Cadence Pharmaceuticals Inc   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; CYTOMEGALOVIRUS VACCINE; GAMMA INTERFERON; GLYCOPROTEIN B; PHOSPHOPROTEIN 65; POLOXAMER; VCL CB01; VIRUS PROTEIN;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MALAISE; MALE; MEMORY T LYMPHOCYTE; MULTICENTER STUDY; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RIGOR; SIDE EFFECT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS VACCINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; KINETICS; MALE; T-LYMPHOCYTES; TIME FACTORS; VACCINES, DNA;

EID: 46349108117     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/588385     Document Type: Article

References (30)

1. Gershon AA, Gold E, Nankervis GA. Cytomegalovirus. In: Evans AS, Kaslow RA, eds. Viral infections of humans. 4th ed. New York: Plenum Press, 1997:229-51.
2. Pass RF. Cytomegalovirus. In: Knipe DM, Howley PM, eds. Fields virology. 4th ed. Philadelphia: Lippincott Williams & Wilkens, 2001:2675-705.
3. Deayton JR, Sabin CA, Johnson MA, Emery VC, Wilson P, Griffiths PD. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet 2004; 363:2116-21.
4. Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in pregnancy: incidence, transmission to fetus, and clinical outcome. JAMA 1986; 256:1904-8.
5. Stagno S. Cytomegalovirus. In: Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant. Philadelphia: W. B. Saunders, 2001:389-424.
6. Stratton KR, Durch JS, Lawrence RS. In: Vaccines for the 21st century: a tool for decision making. Washington, DC: National Academy Press, 2000:1-10, 165-171.
7. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloblative compared with myeloblative allogeneic stem cell transplantation: a matched control study. Blood 2002; 99:1978-85.
8. Junghanss C, Storb R, Maris MB, et al. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloblative allogeneic stem cell transplantation. Br J Haematol 2003; 123:662-70.
9. Hirsch MS. Cytomegalovirus and human herpesvirus types 6, 7, and 8. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill, 2005:1049-53.
10. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185:273-82.
11. Boeckh M, Fries B, Nichols WG. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant 2004; 8(Suppl 5):19-27.
12. Gamadia LE, Remmerswaal EBM, Weel JF, Bemelman F, van Lier RAW, Ten Berge IJM. Primary immune responses to human CMV: a critical role for IFN-γ-producing CD4+ T cells in protection against CMV disease. Blood 2003; 101:2686-92.
13. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202:379-86.
14. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202:673-85.
15. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003; 289:1008-11.
16. Selinsky C, Luke C, Wloch M, et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum Vaccin 2005; 1:16-23.
17. Goonetilleke N, Moore S, Dally L, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 2006; 80:4717-28.
18. Doh SG, Vahlsing HL, Hartikka J, Liang X, Manthorpe M. Spatial-temporal patterns of gene expression in mouse skeletal muscle after injection of lacZ plasmid DNA. Gene Ther 1997; 4:648-63.
19. Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell 2006; 124:677-81.
20. Hanke T, McMichael AJ, Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 2007; 88:1-12.
21. Keating SM, Bejon P, Berthoud T, et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol 2005; 175:5675-80.
22. Adler SP, Plotkin SA, Gonczol E, et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 1999; 180:843-6.
23. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362:1375-7.
24. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038-44.
25. Plotkin SA, Higgins R, Kurtz JB, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994; 58:1176-8.
26. Reusser P, Cathomas G, Attenhofer R, Tamm M, Thiel G. Cytomegalovirus (CMV)-specific T-cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 1999; 180:247-53.
27. Schleiss MR, Bourne N, Bernstein DI. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J Infect Dis 2003; 188:1868-74.
28. Schleiss MR, Lacayo JC, Belkaid Y, et al. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 2007; 195:789-98.
29. Schleiss M. Progress in cytomegalovirus vaccine development. Herpes 2005; 12:66-75.
30. Mocarski ES Jr. Immumodulation by cytomegalovirus: manipulative strategies beyond evasion. Trends Microbiol 2002; 10:332-9.